EGFR and familial pancreatic carcinoma: We therefore evaluated the combinatory effects of natural products with gemcitabine (Figure 4), as well as with the targeted agent gefitinib, an EGFR inhibitor, since EGFR inhibition has shown promising activity in pancreatic cancer, in the MIA PaCa-2 cell line (Figure 5) [64].